Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin and Anlotinib in Metastatic HER2-Negative Breast Cancer
NCT04624711Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of eribulin and anlotinib in breast cancer, sponsored by Jiangsu Provincial People's Hospital. Status: unknown.
02
Drugs
eribulinanlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04624711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04624711.